摘要
目的:探讨泛福舒与氯雷他定治疗儿童反复呼吸道感染对体液免疫的影响,为临床治疗提供参考。方法:80例反复呼吸道感染患儿根据入院顺序把上述患者平分为两组-治疗组与对照组各40例,治疗组给予泛福舒治疗,对照组给予氯雷他定治疗。结果:经过治疗后,治疗组40例显效20例,有效20例,无效0例,总有效率100%。对照组40例显效1 2例,有效20例,无效8例,总有效率70.0%,经过统计学分析,治疗组的临床疗效明显好于对照组(P<0.05)。治疗组治疗前IgG、IgA、IgM对比无显著性差异异(P>0.05)。经过治疗后,治疗组的IgG、IgA水平明显上升(P<05),而对照组IgG、IgA水平上升幅度不大。同时两组治疗后IgM水平与治疗前相比都无显著性差异(P>0.05)。结论:泛福舒在儿童反复呼吸道感染治疗能提高治疗疗效,同时促进体液免疫(IgG、IgA)水平的恢复,值得推广应用。
Objective:To explore impact of broncho-vaxom and loratadine in treating children's recurrent Respiratory Tract infection on humoral immunity for the reference of clinical treatment Methods:Eighty children with recurrent respiratory tract infection were equally divided into Treatment Group and Control.Group(each 40 cases) as per admission sequence.Treatment Group was treated with broncho-vaxom;Control Group was treated with loratadine.Results:After treatment,Treatment Group had 20 cases showing a slight effect and 20 effective cases and 0 ineffective cases,with overall effective rate up to 100%.On the other hand,Control Group had 12 cases showing a slight effect and 20 effective cases and 8 ineffective cases,with overall effective rate up to 70.0%.Statistical analysis indicates Treatment Group shows a remarkably better effect than Control Group(P<0.05).Treatment Group showed no significant difference in IgG,IgA,IgM by comparison(P>0.05) before treatment.After treatment,Treatment Group IgG and IgA increased remarkably(P<0.05); however,Control Group IgG,IgA increased slightly.Meanwhile,both groups showed no significant difference(P>0.05) in IgM compared with before treatment.Conclusion:Children's recurrent respiratory tract infection is treated with better effect by broncho-vaxom; restoration of humoral immunity(IgG,IgA) levels is promoted by broncho-vaxom.As a result,its application is worth promoting.
出处
《中国医药导刊》
2011年第9期1554-1555,共2页
Chinese Journal of Medicinal Guide
关键词
泛福舒
氯雷他定
反复呼吸道感染
体液免疫
儿童
Broncho-Vaxom
Loratadine
Recurrent Respiratory Tract Infection
Humoral Immunity
Children
